drug · antibody
belimumab
Phase 3updated 6mo agoby $GSK GSK plc🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 1Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for lupus nephritis and systemic lupus erythematosus and 17 investigational indications.
indications
indications
Lupus
targets
Tumor necrosis factor ligand superfamily member 13B
all catalysts(0)
nothing on the calendar yet
Trials studying belimumab
- phase1A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- phase3A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- phase3A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- phase2Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
- phase2Belimumab With Rituximab for Primary Membranous Nephropathy
- phase2Belimumab in Autoimmune Hepatitis
- phase2Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized
- phase2Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
News(5)
- Biogen’s big lupus bet gets boost from new durability data for skin diseaseAll signs continue to point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin within one year in patients with cutaneous lupus in a mid-stage study.…biospace · 1mo ago
- Beeline flies into phase 3 as oral lupus drug soars past placeboA phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.fiercebiotech · 2mo ago
- AstraZeneca scores in lung cancer; Sandoz inks a China dealA combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.biopharma_dive · 3mo ago
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.biospace · 3mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that